A global phase IV, double-blind, placebo-controlled, randomized trial to evaluate the effectiveness of detrusitol [tolterodine] sr 4mg on patient's perception of bladder condition (PPBC)
Latest Information Update: 29 Jul 2021
Price :
$35 *
At a glance
- Drugs Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Nov 2012 Planned number of patients changed from 600 to 730 as reported by European Clinical Trials Database record.
- 01 Dec 2008 Updated trial centres.
- 30 Aug 2006 Status change